2021 American Transplant Congress
Cyp3a5 Extensive Metabolizer Phenotype May be Associated with an Increase in Class 2 Donor Specific Antibodies and Antibody-Mediated Rejection
*Purpose: Tacrolimus (TAC) metabolism is highly dependent on CYP3A5, yet there is limited data on the effect of CYP3A5 genetic polymorphisms in heart transplant recipients…2021 American Transplant Congress
Managing the Significant Drug-Drug Interaction Between Tacrolimus and Letermovir in Solid Organ Transplant Recipients
NewYork-Presbyterian Hospital, New York, NY
*Purpose: Letermovir does not appear to share cross-resistance with ganciclovir and is not associated with nephrotoxicity or myelosuppressive effects, making it an attractive option for…2021 American Transplant Congress
Relationship Between Tacrolimus Blood Levels and Covid-19 Pandemic in Kidney Transplant Recipients
*Purpose: The novel coronavirus 2019 infection (COVID-19) caused a pandemic, prompting Tokyo, Japan, to restrict on the free movement of people in March 2020. Kidney…2021 American Transplant Congress
A Comparison of Belatacept Conversion Regimens from Calcineurin Inhibitor-Based Immunosuppression
Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: Outcomes with varying belatacept conversion protocols from calcineurin inhibitor (CNI)-based immunosuppression have been published but no standard protocol has been established. Beginning in 2012,…2021 American Transplant Congress
Higher Calcineurin Inhibitor Levels Associate with Graft Outcomes in Kidney Recipients with De Novo Donor-specific Antibodies of Either Hla Class I or II
Nephrology, CHU de Québec- Université Laval, Québec, QC, Canada
*Purpose: The development of de novo anti-HLA donor specific antibodies (dnDSA) is associated with poorer outcomes in kidney transplant recipients. We and other previously reported…2021 American Transplant Congress
Evaluation of the Conversion from Tacrolimus to Sirolimus in Liver Transplant Recipients
1Mercer University College of Pharmacy, Atlanta, GA, 2Emory University Hospital, Atlanta, GA
*Purpose: The purpose of this study was to compare outcomes in liver transplant patients maintained on standard calcineurin inhibitor (CNI) therapy with tacrolimus versus those…2021 American Transplant Congress
Early Reduction of Tacrolimus Trough Levels Improves Long-term Kidney Function without Increase in Incidence of Acr
*Purpose: We examined the impact of clinical practice management of tacrolimus trough levels in liver transplant recipients on kidney function and incidence of rejection in…2020 American Transplant Congress
Delayed Introduction of Mammalian Inhibitors of Rapamycin (mTOR) Post Kidney Transplantation Might Avoid the Chronic Nephrotoxicity of Calcineurin Inhibitors. Herein We Are Reporting an Eight-Years Single Center Experience of mTOR-Based Immunosuppression Regimen in Comparison with Cyclosporin-Based Regimen
*Purpose: Delayed introduction of mTOR inhibitors post kidney transplantation might avoid the chronic nephrotoxicity of CNI: eight-years single center experience.*Methods: This is a retrospective analysis…2020 American Transplant Congress
Clinical Study of Standard versus Reduced Dose Tacrolimus Combined with Generic Mycophenolate Mofetil in De Novo Kidney Transplantation
Department of Surgery, Ajou University Medical School, Suwon, Korea, Republic of
*Purpose: The lowering of calcineurin inhibitor exposure is possibly considered as the proper strategy to prevent calcineurin inhibitor induced nephrotoxicity in kidney transplant. This clinical…2020 American Transplant Congress
Prospective, Randomized Study of Conversion from Calcineurin Inhibitor (CNI)- to Belatacept (BELA)-Based Maintenance Immunosuppression in Renal Transplant Recipients
*Purpose: CNIs are associated with adverse systemic and nephrotoxic effects that negatively impact long-term patient and graft survival. In a phase 2 study, switching renal…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 16
- Next Page »